CFDA Says Regulatory Reform Needs Market Push: DIA China Meeting
This article was originally published in PharmAsia News
China FDA plans to push reforms by looking to markets for ideas and feedback, delegating tasks to provincial branches, procuring third-party services, and considering a drug review fee increase, says CFDA deputy commissioner Yin Li.
You may also be interested in...
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.
China has stepped up its support for the World Health Organization just as the US is ratcheting up its criticism of both the global health body and China, as policy observers watch closely for any signs the tense bilateral relationship may spill over to the health sector.